drugset / Trial / NCT00129948
Study for Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is a phase 2, single-arm, open-label, multi-center study to establish the safety and efficacy of Troxatyl™ (troxacitabine) administered as a continuous infusion for 5 days to subjects with AML.
Timeline
- Start
- 2005-07
- Primary completion
- —
- Completion
- 2007-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Troxacitabine | Small molecule | 12 mg/m2 | Intravenous |